The ACTG 076 trial, conducted in the United States and Europe, showed that zidovudine given to the mother during delivery and to the infant for six weeks could reduce HIV mother to child transmission by two-thirds. Because of the high cost and compliance problems, however, including the use of intravenous drug during delivery, the lengthy treatment is not optimal. This study is designed to answer the question of whether the duration of prophylactic ZDV treatment can be reduced without increasing the risk of transmission. The proposed study is a Phase II/III double-blind, randomized, controlled, equivalence trial in which the Principal Investigator and his associates will compare long vs. shortened ZDV regimens on the prevention of HIV-1 mother-to-child transmission. The objectives are to: (1) test the equivalence of shorted ZDV regimens administered to pregnant women and their infants, with a long regime of proven efficacy; (2) assess the safety and tolerance of ZDV in mothers and infants; (3) study the pharmacokinetics of ZDV administered orally to pregnant women during labor and delivery; and )4) study the factors associated with transmission related to maternal health, viral replication, phenotype, genotype, and delivery. The study will be conducted in Thailand (Bankok and norther provinces), as a collaborative effort between Harvard, Mahidol, and Chiang Mai Universities and the Ministry of Public Health of the Kingdom of Thailand. Approximately 1500 mother-child pairs will be enrolled in the study; all eligible women will receive ZDV prophylaxis during pregnancy as will their infants after delivery, in a randomized 2 X 2 factorial design. The women will be randomized at 28 weeks of gestation to receive: (1) prenatal treatment beginning at 28 weeks gestation plus 6 weeks of infant treatment; (2) prenatal treatment beginning at 28 weeks gestation plus 3 to 4 days of infant treatment; (3) prenatal treatment beginning at 34 weeks plus 6 weeks of infant treatment, and (4) a shortened course prenatal treatment at 34 weeks plus 3 to 4 days infant treatment. The primary endpoint is HIV infection in the infant as defined by positive polymerase chain reaction (PCR) on two sequential samples and confirmed by a serology 18 months post delivery. Secondary endpoints include: (1) the timing of transmission in utero as defined by a positive PCR within the first 48 hours; (2) the safety and tolerance of ZDV in the mother and infant and a pharmacodynamic study of oral ZDV. The quantification of maternal viral load, assessment of SCV resistance, and phenotypic characterization of virus isolates will be done in a nested case-control study of 40 mothers of infected infants and 80 mothers of uninfected infants.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD033326-03
Application #
2673891
Study Section
AIDS and Related Research Study Section 2 (ARRB)
Program Officer
Nugent, Robert
Project Start
1996-09-01
Project End
2001-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Harvard University
Department
Biology
Type
Schools of Public Health
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Balasubramanian, Raji; Fowler, Mary Glenn; Dominguez, Kenneth et al. (2017) Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1. AIDS 31:2465-2474
Sripan, Patumrat; Le Coeur, Sophie; Amzal, Billy et al. (2015) Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. PLoS One 10:e0126647
Chaillon, Antoine; Samleerat, Tanawan; Zoveda, Faustine et al. (2014) Estimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution model. PLoS One 9:e90421
Collins, Intira Jeannie; Cairns, John; Ngo-Giang-Huong, Nicole et al. (2014) Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand. PLoS One 9:e91004
Collins, Intira; Cairns, John; Le Coeur, Sophie et al. (2013) Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. J Acquir Immune Defic Syndr 64:95-102
Khamduang, Woottichai; Gaudy-Graffin, Catherine; Ngo-Giang-Huong, Nicole et al. (2013) Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring. J Clin Virol 58:415-21
Collins, Intira J; Cairns, John; Jourdain, Gonzague et al. (2012) Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy. AIDS 26:1943-52
Khamduang, Woottichai; Jourdain, Gonzague; Sirirungsi, Wasna et al. (2011) The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers. J Acquir Immune Defic Syndr 58:188-92
Lallemant, Marc; Ngo-Giang-Huong, Nicole; Jourdain, Gonzague et al. (2010) Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 50:898-908
Collins, Intira J; Jourdain, Gonzague; Hansudewechakul, Rawiwan et al. (2010) Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis 51:1449-57

Showing the most recent 10 out of 28 publications